Literature DB >> 6331306

Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis.

H Gadler, A Larsson, E Sølver.   

Abstract

An application of the nucleic acid hybridization technique to screen effects of antiherpes compounds on herpes simplex virus type 1 (HSV-1) DNA synthesis is described. Whole cells are applied to nitrocellulose filters, their DNA is denatured and fixed to the filter. The resulting DNA spots are hybridized to cloned nick-translated HSV-1 DNA and the amount of hybridization is monitored by autoradiography or scintillation counting. Six antiherpes compounds: bromovinyldeoxyuridine, acyclovir, (R)- and (S)-enantiomers of 9-(3,4-dihydroxybutyl)guanine, 9-(4-hydroxybutyl)guanine and forscarnet, were evaluated for their effects on HSV-1 DNA synthesis. The most active compounds were bromovinyldeoxyuridine and acyclovir, with mean 50% inhibition values (IC50) for four different HSV-1 strains of 0.3 microM and 0.8 microM, respectively. The (R)-enantiomer of the new antiherpes compound 9-(3,4-dihydroxybutyl)guanine was found to be more active than the (S)-enantiomer, with mean IC50s of 6.5 and 14 microM, respectively, while mean IC50s of 2.5 and 68 microM were obtained for 9-(4-hydroxybutyl)guanine and foscarnet, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331306     DOI: 10.1016/0166-3542(84)90026-3

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 2.  Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease.

Authors:  D Pavan-Langston
Journal:  Trans Am Ophthalmol Soc       Date:  1990

3.  Rapid herpes simplex virus susceptibility testing using an enzyme-linked immunosorbent assay performed in situ on fixed virus-infected monolayers.

Authors:  G P Rabalais; M J Levin; F E Berkowitz
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus.

Authors:  E M Swierkosz; D R Scholl; J L Brown; J D Jollick; C A Gleaves
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

5.  Comparative methods for detection of thymidine kinase-deficient herpes simplex virus type 1 strains.

Authors:  J Harmenberg; V A Sundqvist; H Gadler; B Levén; G Brännström; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

6.  Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir.

Authors:  A Larsson; K Stenberg; A C Ericson; U Haglund; W A Yisak; N G Johansson; B Oberg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

Authors:  D L Earnshaw; T H Bacon; S J Darlison; K Edmonds; R M Perkins; R A Vere Hodge
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Polymerization activity of an alpha-like DNA polymerase requires a conserved 3'-5' exonuclease active site.

Authors:  J S Gibbs; K Weisshart; P Digard; A deBruynKops; D M Knipe; D M Coen
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

Review 9.  A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1.

Authors:  Sara M Thomasy; David J Maggs
Journal:  Vet Ophthalmol       Date:  2016-04-19       Impact factor: 1.644

10.  Inhibition of herpes simplex virus production in vitro by cyclosporin A.

Authors:  A Vahlne; P A Larsson; P Horal; J Ahlmén; B Svennerholm; J S Gronowitz; S Olofsson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.